The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.
These tests are critically important because a confirmed diagnosis is required for a patient to begin receiving free treatment through our donation programs – and access to treatment is access to life.
We extend our deepest thanks to the dedicated team at Fred Hutch and the hundreds of physicians and nurses around the world who work tirelessly to support their patients. Thanks to your efforts, we not only met but exceeded our initial goal – testing one new patient per day for an entire year.
Here’s how the patient numbers break down by country:
About Spot On CML
Launched in 2017, Spot On CML is a groundbreaking collaboration between The Max Foundation and Fred Hutchinson Cancer Research Center (Fred Hutch) to increase access to testing for chronic myeloid leukemia (CML) patients in under-resourced countries. The initiative utilizes a special process developed by Fred Hutch researcher and The Max Foundation board member Dr. Jerry Radich. In it, paper test cards are spotted with dried blood samples and mailed to Fred Hutch from all over the world, where researchers perform testing on the samples free-of-charge.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
March 9 marks the devastating anniversary of the day my stepson Max died after a three-year battle with cancer. Max was 17 years old. I have dedicated most of the last 34 years to galvanizing the global community to help families avoid the suffering of the premature loss of their loved one. In the process,….
In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low and middle income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.
The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….
